- Home
- KALV vs NPFD Comparison
KALV vs NPFD Comparison
Compare KALV & NPFD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- NPFD
- Stock Information
- Founded
- KALV N/A
- NPFD 2021
- Country
- KALV United States
- NPFD United States
- Employees
- KALV N/A
- NPFD N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- NPFD Trusts Except Educational Religious and Charitable
- Sector
- KALV Health Care
- NPFD Finance
- Exchange
- KALV Nasdaq
- NPFD Nasdaq
- Market Cap
- KALV 796.4M
- NPFD 474.6M
- IPO Year
- KALV N/A
- NPFD N/A
- Fundamental
- Price
- KALV $14.01
- NPFD $19.63
- Analyst Decision
- KALV Strong Buy
- NPFD
- Analyst Count
- KALV 8
- NPFD 0
- Target Price
- KALV $26.43
- NPFD N/A
- AVG Volume (30 Days)
- KALV 1.0M
- NPFD 64.7K
- Earning Date
- KALV 09-11-2025
- NPFD 01-01-0001
- Dividend Yield
- KALV N/A
- NPFD 6.28%
- EPS Growth
- KALV N/A
- NPFD N/A
- EPS
- KALV N/A
- NPFD N/A
- Revenue
- KALV $1,426,000.00
- NPFD N/A
- Revenue This Year
- KALV N/A
- NPFD N/A
- Revenue Next Year
- KALV $221.95
- NPFD N/A
- P/E Ratio
- KALV N/A
- NPFD N/A
- Revenue Growth
- KALV N/A
- NPFD N/A
- 52 Week Low
- KALV $7.30
- NPFD $14.50
- 52 Week High
- KALV $17.28
- NPFD $18.07
- Technical
- Relative Strength Index (RSI)
- KALV 48.69
- NPFD 58.26
- Support Level
- KALV $13.26
- NPFD $19.59
- Resistance Level
- KALV $17.28
- NPFD $19.70
- Average True Range (ATR)
- KALV 1.00
- NPFD 0.13
- MACD
- KALV 0.08
- NPFD -0.01
- Stochastic Oscillator
- KALV 25.34
- NPFD 65.46
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About NPFD Nuveen Variable Rate Preferred & Income Fund
Nuveen Variable Rate Preferred&Income is a newly organized, diversified, closed-end management investment company. The Fund's investment objective is to seek to provide a high level of current income and total return.